All In Biotech

Drug Trial Radar · NCT06238635

Dostarlimab and Cobolimab in Advanced Cervical Cancer

A Phase 2 Study of Dostarlimab in Combination With Cobolimab in Advanced Cervical Cancer

Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

66

Planned (sponsor's estimate)

Start

Mar 11, 2024

Primary completion

Dec 1, 2026

Study completion Jul 15, 2027

Sponsor

Lead sponsor
Meghan SheaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
GlaxoSmithKline
First posted
Feb 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research is being done to determine how effective dostarlimab in combination with cobolimab is in metastatic or recurrent cervical cancer.

Conditions

  • Cervical Cancer
  • Advanced Cervical Carcinoma
  • Metastatic Cervical Cancer
  • Metastatic Cervical Carcinoma
  • Recurrent Cervical Carcinoma

Interventions

  • DostarlimabDrug

    Humanized monoclonal antibody, 50mg/mL type 1 borosilicate clear glass vial, via intravenous infusion per protocol.

  • CobolimabDrug

    Humanized anti-TIM-3 monoclonal antibody, 20mg/mL single-use vial, via intravenous infusion per protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) Based on irRECISTTime frame: Up to 2 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.